Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- King Pharmaceuticals Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionThank you, Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question is from Corey Davis from Natixis. Please go ahead. Corey Davis - Natixis Bleichroeder Thanks very much. I just wanted to ask a couple of questions about the Alpharma acquisition. Just kidding....
- Earnings calls 2008-11-07
Additional Resources
- Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
- GLASGOW, Scotland -- Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY([R]), an investigational drug to treat chronic pain. The final data confirm REMOXY provides effective around-the-clock analgesia within a patented formulation...
- Research articles 2008-08-19
- King Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionThank you. The floor is now open for questions. [Operator Instructions]. Our first question comes from Greg Gilbert of Merrill Lynch. Please state your question. Gregory Gilbert - Merrill Lynch Thanks. Good morning. Can you give us your latest thoughts on the competitive environment in the Thrombin market...
- Earnings calls 2008-08-07
- DURECT Corporation Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator There is no question at this time Matt Hogan All right, let's wait one minute and see if anyone wants to ask a question, otherwise they can call us later. Operator Ken Trbovich with RBC Capital. I'll un-mute him now. Matt Hogan Okay. Ken Trbovich - RBC...
- Earnings calls 2008-05-26
- King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionThank you, Mr. Squicciarino. [Operator Instructions]. And our first question comes from Donald Ellis from Thomas Weisel Partners. Please go ahead. Donald Ellis - Thomas Weisel Partners Thank you, and good morning. First question is regarding SKELAXIN. Year-over-year prescriptions were down about 8.5%, but the revenue reported was...
- Earnings calls 2008-05-08
- Why Pain Therapeutics is Too Risky
- Steve Alexander submits: Pain Therapeutics PITE is a branded pharmaceutical development concern. The company is essentially hitched to King Pharmaceuticals KG, and even more specifically to the success or failure of a single drug - Remoxy, a form of Oxycontin designed to resist chemical and physical manipulation. Let's take a...
- External links 2009-07-26
- King Pharma: Value Play on New Drug Approvals
- Mike Havrilla submits: King Pharma KG is a specialty pharmaceutical company which recently acquired Alpharma for $1.6B and has three pending NDAs at the FDA for new drug approvals and received a complete response late last year for Remoxy (an abuse deterrent form of extended-release oxycodone) along with Pain Therapeutics...
- External links 2009-03-20
- Pain Therapeutics.(F.Y.I.)
- Pain Therapeutics, a South San Francisco biotech company, says it has come up with a tamper-resistant substitute for Purdue Pharma's widely abused time-release painkiller OxyContin. The main ingredient in Remoxy is still the narcotic oxycodone, and the effect still lasts 12 hours, but it will be...
- Research articles 2003-11-13
- King Pharma: FDA Headaches Continue
- EP Vantage submits: As a pain company, King Pharmaceuticals KG might want to get working on a treatment to spare it the agony that the FDA appears intent on continuing to heap upon its head. Yesterday, an advisory committee voted 11-5 not to recommend its heart imaging drug Corvue...
- External links 2009-07-31
- King Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Our first question comes from the line of Louise Chen of Collins Stewart. Please state your question. Louise Chen -- Collins Stewart My question was with respect to your abuse-deterrent opioid franchise. Based on comments made by the FDA, it sounds like they do want...
- Earnings calls 2009-08-07
- << Previous
- page 1 of 1
- Next >>
Presented by American Express